Literature DB >> 21862728

Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Anton H van den Meiracker, A H Jan Danser, Stefan Sleijfer, Mariette H W Kappers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21862728     DOI： 10.1093/jnci/djr328

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

Authors:  Nilka de Jesus-Gonzalez; Emily Robinson; Radostin Penchev; Margaret von Mehren; Michael C Heinrich; William Tap; Qian Wang; George Demetri; Suzanne George; Benjamin D Humphreys
Journal:  Am J Hypertens       Date:  2012-07-12       Impact factor: 2.689

2.  Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism.

Authors:  Joevin Sourdon; Franck Lager; Thomas Viel; Daniel Balvay; Rebecca Moorhouse; Evangeline Bennana; Gilles Renault; Pierre-Louis Tharaux; Neeraj Dhaun; Bertrand Tavitian
Journal:  Theranostics       Date:  2017-07-08       Impact factor: 11.556

Review 3.  Hypertension in cancer patients treated with anti-angiogenic based regimens.

Authors:  Yishay Wasserstrum; Ran Kornowski; Pia Raanani; Avi Leader; Oren Pasvolsky; Zaza Iakobishvili
Journal:  Cardiooncology       Date:  2015-12-07

4.  The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma.

Authors:  Pu Wu; Jinyuan Shi; Wei Sun; Hao Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.

Authors:  Petri Bono; Stephane Oudard; Istvan Bodrogi; Thomas E Hutson; Bernard Escudier; Jean-Pascal Machiels; John A Thompson; Robert A Figlin; Alain Ravaud; Mert Basaran; Camillo Porta; Sergio Bracarda; Thomas Brechenmacher; Chinjune Lin; Maurizio Voi; Viktor Grunwald; Robert J Motzer
Journal:  Clin Genitourin Cancer       Date:  2016-04-27       Impact factor: 2.872
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.